Acloproxalap

The 2024 Alcoholic Hepatitis Pipeline report highlights significant advancements in treatment therapies, with over 10 companies developing innovative solutions. Key developments include Breakthrough Therapy designation for larsucosterol and progress in Aldeyra Therapeutics' RASP modulator platform. The report provides a comprehensive overview of the clinical development scenario, therapeutic assessments, and market dynamics.

Aldeyra Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for reproxalap, targeting the signs and symptoms of dry eye disease (DED).

Aldeyra Therapeutics' reproxalap ophthalmic solution met the primary endpoint in a Phase 3 dry eye chamber trial, demonstrating statistical superiority over the vehicle for ocular discomfort.

Aldeyra Therapeutics plans to resubmit its NDA for reproxalap to treat dry eye disease after addressing FDA concerns.

Aldeyra Therapeutics' NDA for Reproxalap in dry eye disease has a PDUFA date of November 23, 2023, with commercial preparations underway, highlighting its potential in a $23 billion market.